A T-cell therapy developed by Orca Bio, a private biotech company, significantly reduced the risk of a debilitating immune ...

CAR-T cell therapy has revolutionized the treatment of relapsed and refractory B-acute lymphoblastic leukemia (B-ALL), with ...

CART, a next-gen CAR-T therapy for improved targeting and functionality to address this. “ALA-CART improves the ability of ...

Researchers uncover how leukemia drains T cells' energy, paving the way for stronger cancer immunotherapy and enhancing CAR T ...

My survival is based on research. With limited NIH funding, I fear that my life, and the lives of others, will be left ...

Scientists have supercharged CAR-T therapy, making it more powerful against elusive cancer cells that usually escape ...

Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease ...

CAR-T pipeline advances, with blood cancers at the forefront of development, driving new treatment innovations.

Previously reported Phase 1/2 data on WU-CART-007 demonstrated clinically manageable safety and evidence of anti-leukemic activity with an ...

Researchers have successfully developed a supercharged iteration of CAR-T cell therapy that can enhance the effectiveness and longevity of the cells, particularly against cancer cells that are harder ...